Consuming Amino LP7, a specific combination of essential amino acidsAmino acids are a set of organic compounds used to build proteins. There are about 500 naturally occurring known amino acids, though only 20 appear in the genetic code. Proteins consist of one or more chains of amino acids called polypeptides. The sequence of the amino acid chain causes the polypeptide to fold into a shape that is biologically active. The amino acid sequences of proteins are encoded in the genes. Nine proteinogenic amino acids are called “essential” for humans because they cannot be produced from other compounds by the human body and so must be taken in as food.”>amino acids, could inhibit the development of dementia, shows a study from Japan.
Protein intake is known to be vital for maintaining brain function in older individuals. Now, using a mouse model of Alzheimer’sAlzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.”>Alzheimer’s disease, researchers have shown that the intake of a specific set of amino acids can inhibit the death of brain cells, protect the connections between them, and reduce inflammation, preserving brain function. Their research suggests that this amino acidAny substance that when dissolved in water, gives a pH less than 7.0, or donates a hydrogen ion.”>acid combination called Amino LP7 can hinder the development of dementia, including Alzheimer’s disease.
Dementia—a condition involving the extreme loss of cognitive function—is caused by a variety of disorders, including Alzheimer’s disease. According to World Health Organization estimates, approximately 10 million individuals worldwide develop dementia every year, indicating the high psychological and social impact of this condition. Dementia mainly affects older people, and so far, simple and effective strategies for preventing this condition have remained elusive.
In a recent study published in Science Advances, Japanese researchers showed that a low protein diet can accelerate brain degeneration in mouse models of Alzheimer’s disease. More importantly, they found that Amino LP7—a supplement containing seven specific amino acids—can slow down brain degeneration and dementia development in these animals. Their work expands on previous studies, which have demonstrated the effectiveness of Amino LP7 in improving cognitive function.
Brain atrophy occurred in the Alzheimer’s mouse model, which was accelerated by a low protein diet and suppressed by Amino LP7. Arrowheads indicate the ventricles, which were observed to grow larger in tandem with brain atrophy. Credit: National Institutes for Quantum Science and Technology
Dr. Makoto Higuchi from the National Institutes for Quantum Sciences and Technology, one of the lead scientists on the study, explains, “In older individuals, low protein diets are linked to poor maintenance of brain function. Amino acids are the building blocks of proteins. So, we wanted to understand whether supplementation with essential amino acids can protect the brains of older people from dementia, and if yes, what mechanisms would contribute to this protective effect.”
First, the researchers studied how a low protein diet affects the brain in mouse models of Alzheimer’s disease, which generally demonstrate neurodegeneration and abnormal protein aggregates called “Tau” aggregates in the brain. They found that mice consuming a low protein diet not only showed accelerated brain degeneration but also had signs of poor neuronal connectivity. Interestingly, these effects were reversed after supplementation with Amino LP7, indicating that the combination of seven specific amino acids could inhibit brain damage.
Next, the research team examined how Amino LP7 affects different signs of brain degeneration in the Alzheimer’s model. Untreated mice showed high levels of progressive brain degeneration, but Amino LP7 treatment suppressed neuronal death and thereby reduced brain degeneration, even though the Tau aggregates remained. According to Dr. Akihiko Kitamura, who also led this study, “Tau plaques in the brain are characteristic of Alzheimer’s and most treatments target them. However, we have shown that it is possible to overcome this Tau deposition and prevent brain atrophy via supplementation with Amino LP7.”
Next, to understand how Amino LP7 protects the brain, the researchers comprehensively analyzed the gene-level changes induced by Amino LP7. Their findings were quite encouraging. They observed that Amino LP7 reduces brain inflammation and also prevents kynurenine, an inflammation inducer, from entering the brain, thereby preventing inflammatory immune cells from attacking neurons. They also found that Amino LP7 reduces neuronal death and improves neuronal connectivity, improving brain function.
“These results suggest that essential amino acids can help maintain balance in the brain and prevent brain deterioration. Our study is the first to report that specific amino acids can hinder the development of dementia,” said Dr. Hideaki Sato and Dr. Yuhei Takado, both of whom majorly contributed to the study. “Although our study was performed in mice, it brings hope that amino acid intake could also modify the development of dementia in humans, including Alzheimer’s disease,” they add.
The study by this research group throws open several avenues for a better understanding of how dementias occur and how they can be prevented. Given that Amino LP7 improves brain function in older people without cognitive impairment, their findings suggest that it could also be effective in people with cognitive dysfunction.
Indeed, this patent-pending supplement could one day help millions worldwide live an improved, dementia-free life.
Reference: “Neurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model” by Hideaki Sato, Yuhei Takado, Sakiko Toyoda, Masako Tsukamoto-Yasui, Keiichiro Minatohara, Hiroyuki Takuwa, Takuya Urushihata, Manami Takahashi, Masafumi Shimojo, Maiko Ono, Jun Maeda, Asumi Orihara, Naruhiko Sahara, Ichio Aoki, Sachise Karakawa, Muneki Isokawa, Noriko Kawasaki, Mika Kawasaki, Satoko Ueno, Mayuka Kanda, Mai Nishimura, Katsuya Suzuki, Akira Mitsui, Kenji Nagao, Akihiko Kitamura and Makoto Higuchi, 22 October 2021, Science Advances.
DOI: 10.1126/sciadv.abd5046
The present work was supported by Ajinomoto Co., Inc., Grants-in-Aid for Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS; 18dm0207018 and 19dm0207072), JST grant number JPMJMS2024 and AMED grant number 20356533 to M.H., and grant for Young Scientists (20 K15910 to K.M.)
About National Institutes for Quantum Science and Technology, Japan
The National Institutes for Quantum Science and Technology (QST) was established in April 2016 to promote quantum science and technology in a comprehensive and integrated manner. The new organization was formed from the merger of the National Institute of Radiological Sciences (NIRS) with certain operations that were previously undertaken by the Japan Atomic Energy Agency (JAEA).
QST’s mission is to raise the level of quantum and radiological sciences and technologies through its commitment to research and development into quantum science and technology, the effect of radiation on humans, radiation emergency medicine, and the medical use of radiation.
To ensure that research and development delivers significant academic, social and economic impacts, and to maximize benefits from global innovation, QST is striving to establish world-leading research and development platforms, explore new fields, and serve as a center for radiation protection and radiation emergency medicine.
About Dr. Makoto Higuchi from National Institutes for Quantum Science and Technology, Japan
Dr. Makoto Higuchi is a renowned neuroscientist and heads the Department of Functional Brain Imaging at the National Institutes for Quantum Sciences and Technology, Japan. In 1997, he was awarded a Ph.D. in Medicine from Tohoku University Graduate School of Medicine, and he completed his postdoctoral training in the University of Pennsylvania School of Medicine. His primary research interest lies in translational molecular imaging aimed at elucidating the pathophysiology of neuropsychiatric disorders such as schizophrenia, depression, and Alzheimer’s disease. He is credited for the development of agents for imaging pathological tau protein deposits in neurodegenerative diseases.
Source: SciTechDaily
